Structure-activity relationships for a collection of structurally diverse inhibitors of purine nucleoside phosphorylase

被引:23
作者
Andricopulo, AD [1 ]
Yunes, RA
机构
[1] Univ Michigan, Coll Pharm, Ann Arbor, MI 48109 USA
[2] Univ Fed Santa Catarina, Dept Chem, BR-88040900 Florianopolis, SC, Brazil
关键词
purine nucleoside phosphorylase; enzyme inhibition; QSAR model;
D O I
10.1248/cpb.49.10
中图分类号
R914 [药物化学];
学科分类号
100701 ;
摘要
Values of inhibition constants, K-i, and concentrations required for 50% inhibition, IC50, for a collection of structurally diverse competitive inhibitors of calf spleen purine nucleoside phosphorylase have been determined employing inosine as substrate. These values have been employed to create predictive quantitative structure-activity relationships (QSAR) which link structure to values of K-i and IC50. These QSAR models have substantial power to predict values and the associated uncertainties for K-i and IC50 for unknown, structurally diverse inhibitors of purine nucleoside phosphorylase.
引用
收藏
页码:10 / 17
页数:8
相关论文
共 11 条
[1]  
Andricopulo AD, 1999, PHARMAZIE, V54, P698
[2]   Guanine, pyrazolo[3,4-d] pyrimidine, and triazolo[4,5-d] pyrimidine (8-azaguanine) phosphonate acyclic derivatives as inhibitors of purine nucleoside phosphorylase [J].
Beauchamp, LM ;
Tuttle, JV ;
Rodriguez, ME ;
Sznaidman, ML .
JOURNAL OF MEDICINAL CHEMISTRY, 1996, 39 (04) :949-956
[3]  
Breneman CM, 1997, J COMPUT CHEM, V18, P182, DOI 10.1002/(SICI)1096-987X(19970130)18:2<182::AID-JCC4>3.0.CO
[4]  
2-R
[5]   ELECTRON-DENSITY MODELING OF LARGE SYSTEMS USING THE TRANSFERABLE ATOM EQUIVALENT METHOD [J].
BRENEMAN, CM ;
THOMPSON, TR ;
RHEM, M ;
DUNG, M .
COMPUTERS & CHEMISTRY, 1995, 19 (03) :161-&
[6]   Structure-activity relationships for a class of inhibitors of purine nucleoside phosphorylase [J].
Farutin, V ;
Masterson, L ;
Andricopulo, AD ;
Cheng, JM ;
Riley, B ;
Hakimi, R ;
Frazer, JW ;
Cordes, EH .
JOURNAL OF MEDICINAL CHEMISTRY, 1999, 42 (13) :2422-2431
[7]   Calf spleen purine nucleoside phosphorylase complexed with substrates and substrate analogues [J].
Mao, C ;
Cook, WJ ;
Zhou, M ;
Federov, AA ;
Almo, SC ;
Ealick, SE .
BIOCHEMISTRY, 1998, 37 (20) :7135-7146
[8]  
Montgomery J. A., 1994, EXPERT OPIN INV DRUG, V3, P1303
[9]  
Morris PE, 1998, EXPERT OPIN THER PAT, V8, P283
[10]  
SIRCAR J C, 1988, Drugs of the Future, V13, P653